Return to Article Details
AN UPDATE ON CURRENT USAGE OF SGLT2-INHIBITORS IN HEART FAILURE WITH REDUCED EJECTION FRACTION: SPECIAL FOCUS ON DAPAGLIFLOZIN
Download
Download PDF